Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study
26. März 2015 09:00 ET
|
Zogenix
SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results
10. März 2015 16:05 ET
|
Zogenix
Clinical and Regulatory Update
Received FDA approval for new formulation of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek™
On track to begin...
Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing Plus Potential Milestones of $283.5 Million
10. März 2015 16:05 ET
|
Zogenix
Enables planned implementation of new strategic focus to developing a late-stage, high-value CNS pipeline
Conference Call and Webcast on Tuesday, March 10, at 4:30 p.m. ET
Agreement...
Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2014 Financial Results
02. März 2015 16:05 ET
|
Zogenix
SAN DIEGO, March 2, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix Appoints Industry Veteran Renee Tannenbaum to Its Board of Directors
10. Februar 2015 16:01 ET
|
Zogenix
SAN DIEGO, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix to Participate in Leerink Global Healthcare Conference
05. Februar 2015 09:00 ET
|
Zogenix
SAN DIEGO, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER
30. Januar 2015 19:05 ET
|
Zogenix
SAN DIEGO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix Provides Business Update
12. Januar 2015 07:30 ET
|
Zogenix
SAN DIEGO, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference
03. Dezember 2014 16:30 ET
|
Zogenix
SAN DIEGO, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the Safety, Tolerability and Effectiveness of Zohydro(R) ER
01. Dezember 2014 08:30 ET
|
Zogenix
SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...